How AI helps scientists design the next generation of medicines
Quick Answer
AI is transforming biologic drug development by enhancing candidate design, reducing timelines by up to 50%, and enabling the creation of complex multi-target medicines.
Quick Take
AstraZeneca's AI-driven approach focuses on a build-measure-learn loop, optimizing drug candidates for efficacy and manufacturability, paving the way for previously untreatable diseases.
Key Points
- AI accelerates biologic drug design, reducing discovery timelines by up to 50%.
- AstraZeneca employs a build-measure-learn loop to optimize drug candidates.
- AI narrows down molecular combinations, focusing resources on top candidates.
- The next generation of drugs targets multiple pathways simultaneously.
- AstraZeneca's 'lab of the future' integrates AI and robotics for continuous discovery.
DeepSignal Analysis
What happened
AI is increasingly integrated into biologic drug development, significantly enhancing the design process and reducing timelines. AstraZeneca employs a build-measure-learn approach to optimize drug candidates, enabling the exploration of previously untreatable diseases. The company is also developing a 'lab of the future' to automate and streamline drug discovery.
Key evidence
- AstraZeneca's AI-driven approach aims to reduce drug discovery timelines by up to 50%, according to estimates from McKinsey.
- The company is building a facility in Cambridge, Massachusetts, where AI and robotic automation will create a continuous discovery system.
- AI-assisted design allows AstraZeneca to focus lab resources on top-ranked drug candidates, leading to faster iterations and fewer dead ends.
Why it matters
The integration of AI in drug development could revolutionize the pharmaceutical industry by accelerating the discovery of new medicines and addressing complex diseases. By optimizing candidate selection and automating processes, companies like AstraZeneca aim to bring innovative treatments to market more efficiently. This could ultimately lead to significant advancements in patient care and outcomes.
Source Excerpt
As generative AI captures public attention, a different kind of AI is reshaping drug discovery. Machine learning models are helping to compress decade-long timelines and cracking problems that were previously unsolvable.
Want this in your inbox every morning?
Daily brief at your local 8am — bilingual EN/中文, free.
More from MIT Technology Review
See more →
The Download: OpenAI unveils GPT-Red and heat pumps rise in the US
OpenAI's new GPT-Red automates red-teaming safety evaluations for software, enhancing security against human attackers. Meanwhile, heat pump sales in the US have doubled over 15 years, outperforming natural gas furnaces by 32% in early 2026, despite the expiration of a key tax credit.
